Skip to Content

Jazz Pharmaceuticals PLC JAZZ Stock Quote

| Rating as of

Morningstar‘s Stock Analysis JAZZ

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Raising Jazz’s FVE to $187 on Improved Outlook Thanks to Strong Drug Launches; Shares Undervalued

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Jazz increased its 2022 guidance based on the strong uptake of Xywav (for narcolepsy and idiopathic hypersomnia) and Rylaze (for acute lymphoblastic leukemia), which have generated greater than expected prescriber and patient adoption. As a result, we’ve increased our fair value estimate to $187 per share from $172. We believe shares are currently trading at an attractive entry point in 4-star territory. We maintain our no-moat and negative trend ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics JAZZ

Company Profile JAZZ

Business Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Contact
Waterloo Road, Fifth Floor, Waterloo Exchange
Dublin, D04 E5W7, Ireland
T +353 16347800
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 3,200